# 危机投资模型

Deep Investment Research: Nobel Prize-Winning Gene Editing Therapy, Why Is the Market Only Valuing It at a Quarter of Its Price?
A simple arithmetic problem:
CRISPR Therapeutics has a current market cap of $4.5 billion. Cash on hand is $2.5 billion. $4.5 billion - $2.5 billion = $2 billion.
What is the market pricing at $2 billion?
The world's first FDA-approved CRISPR gene editing therapy + 6 active clinical pipelines + Nobel Prize-level intellectual property + exclusive partnership with Vertex, valued at $110 billion.
But rebuilding these assets from scratch would cost at least $7.2 billion.